Controlled trial of protease inhibitor gabexelate mesilate (FOY) in the treatment of acute pancreatitis

Pancreas

Volumn 2, Issue 6, 1987, Pages 698-700

  Yang, Chaur Young ^a   Chang Chien, Chi Sin ^a   Liaw, Yun Fan ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Acute pancreatitis; Protease inhibitor

Indexed keywords

GABEXATE MESILATE; PROTEINASE INHIBITOR;

ACUTE PANCREATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; FATALITY; HUMAN; PRIORITY JOURNAL;

ACUTE DISEASE; CLINICAL TRIALS; FEMALE; GABEXATE; GUANIDINES; HUMAN; MALE; PANCREATITIS; PROTEASE INHIBITORS; RANDOM ALLOCATION; SUPPORT, NON-U.S. GOV'T;

EID: 0023493713     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/00006676-198711000-00013     Document Type: Article

References (15)

1. Lasson A, Ohlsson K. Acute pancreatitis, the correlation between clinical course, protease inhibitors, and complement and kinin activation. Scand J Gastroenterol 1984; 19: 707-10.
2. Imire CW, Benjamin IS, Ferguson JC, et al. A single-center double-blind trial of Trasylol therapy in primary acute pan-creatitis. BrJ Surg 1978;65:337-41.
3. Medical Research Council Multicentre Trial of glucagon and aprotinin. Death from acute pancreatitis. Lancet 1977;2: 632-5.
4. Medical Research Council Multicentre Trial. Morbidity of acute pancreatitis: The effect of aprotinin and glucagon. Gut 1980;21:334-9.
5. Tamura Y, Hirado M, Okamura K. Synthetic inhibitors of trypsin, plasmin, killikrein, thrombin, Clr and Cl esterase. Biochim Biophys Acta 1977;484:417.
6. Takasugi S, Yonezawa H, Ikei N, Kanno T. Prevention of acute experimental pancreatitis in rats and dogs by intraduodenal infusion of synthetic trypsin inhibitor. Digestion 1982;24:36-41.
7. Goke B, Stockmann F, Muller R, Kankisch PG, Creutzfeldt W. Effect of a specific serine protease inhibitor on the rat pancreas: systemic administration of Camostate and exocrine pancreatic secretion. Digestion 1984;30:171-8.
8. Freise J. Effect of synthetic protease and phospholipase A2 inhibitor gabexate mesilate (FOY) on the clinical course of patients with acute pancreatitis. Fortschr Med 1983; 101: 1431-6.
9. Tanaka N, Tsuchiya R, Ichii K. Comparative clinical study of FOY and trasylol in acute pancreatitis. Adv Exp Med Biol 1979;120B:367-78.
10. Matsunaga E, Sato Y, Nakashima H, Deguchi T, Kojima H, Sagara K. Prophylatic effects of FOY in post-ERCP pancreatitis. Gendai Iryo 1979; 11:1213.
11. Tsai DY, Liaw YF, Chang-Chien CS, Wu CS, Chen PC. A clinical study on acute pancreatitis. J Formosan Med Assoc 1982;81:1168-74.
12. Ranson JHC, Rifkind KM, Roses DF, Fink SD, Eng K, Spencer FC. Prognostic signs and the role of operative management in acute pancreatitis. Surg Gynecol Obstet 1974; 139:69-81.
13. Broyles RW, Lay CM, eds. Statistics in health administration. Vol I. Germantown, Maryland: Aspen Systems, 1979:384-8.
14. Taenaka N, Shimada Y, Hirata T, et al. Gabexate mesilate (FOY) therapy of disseminated intravascular coagulation due to sepsis. Crit Care Med 1983;11:735-8.
15. Lasson A, Ohlsson K. Protease inhibitor in acute human pancreatitis: Correlation between biochemical changes and clinical course. Scand J Gastroenterol 1984;19:779-86.